Elicera Therapeutics
Elicera Therapeutics is a Swedish biopharmaceutical company focused on developing cell and gene therapies for immune-based cancer treatment. Its pipeline centers on proprietary oncology programs, including the CAR T-cell candidate ELC-301 and the oncolytic virus candidate ELC-100, supported by the iTANK platform technology.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueAutologous or engineered cell-based cancer therapies developed for clinical testing.
Virus-based immunotherapy programs designed to attack tumors and stimulate immunity.
iTANK is a proprietary technology intended to enhance immune activation in cell therapies.
Internal discovery, translational work, and clinical development activities for pipeline assets.
Customers
Elicera does not sell commercial medicines; its direct counterparties are mainly research collaborators, clinical trial sites, regulators, grant providers, and potential licensing or partnership partners. The eventual end users of its therapies are oncology patients, especially those with hard-to-treat hematologic and solid tumors. In the current development stage, value is created by advancing clinical data, intellectual property, and partnering optionality rather than by product sales.
Patients enrolled in ELC-301 and ELC-100 studies who receive the investigational therapies.
Hospitals and research centers that administer trials and generate safety/efficacy data.
Biopharma companies that may license or co-develop pipeline assets after proof-of-concept.
EU and Swedish funding bodies that support early-stage R&D and clinical work.
Strategy
Elicera’s strategy is to advance its lead oncology programs through clinical proof-of-concept and build value around the iTANK platform. The company also emphasizes intellectual property protection, external funding, and partnership opportunities to extend development capacity and preserve optionality. Clinical data generation is central because it supports both future regulatory paths and potential outlicensing discussions.
Clinical data is the main value driver for early-stage oncology assets.
iTANK is intended to improve immune activation and broaden therapeutic utility.
External capital and collaboration can extend runway and support development.
Geography
Elicera is headquartered in Sweden, with its head office in Uppsala and an office in Gothenburg. Its development work is organized from Sweden, while the therapeutic opportunity is global because oncology drug candidates are intended for regulated markets in Europe and other regions. The company’s geographic exposure is therefore driven less by current sales and more by where clinical trials, patents, and future approvals may be pursued.
Risks
Elicera faces the typical risks of an early-stage biotech company: clinical failure, regulatory delays, and uncertainty around whether its candidates will show enough efficacy and safety to progress. Because the business depends on patents, external funding, and future commercialization, setbacks in IP protection, financing, or pricing/reimbursement could materially limit value creation. Competition from larger oncology companies also raises the bar for differentiation and partnering.
- Clinical development failureImpact: CriticalLikelihood: Medium
Pipeline value depends on positive Phase I/IIa and preclinical results.
Exposure: ELC-301 and ELC-100 programs
- Financing and dilution riskImpact: HighLikelihood: High
Development-stage biotech typically requires repeated external capital raises.
Exposure - Patent and IP protection riskImpact: HighLikelihood: Medium
The company’s assets rely on enforceable patent coverage in multiple jurisdictions.
Exposure - Commercialization and pricing riskImpact: HighLikelihood: Medium
Even approved therapies may face reimbursement pressure and pricing scrutiny.
Exposure: CAR T-cell therapies and future oncology launches
- Competitive riskImpact: MediumLikelihood: Medium
Large multinational pharma companies can advance competing oncology programs faster.
Exposure: B-cell lymphoma and immuno-oncology
Accounting
Judgemental itemsClinical and preclinical costs are expensed as incurred, directly affecting operating loss.
Impact: Makes earnings highly sensitive to trial activity and development pace
Public grants can be recognized in income and reduce net R&D burden.
Impact: Can materially change reported results from period to period
The company notes no current capitalization of development or patent costs.
Impact: Prevents asset buildup from internally generated pipeline spending
As a development-stage company, liquidity depends on external funding.
Impact: Affects disclosure, valuation, and financial statement presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Elicio Therapeutics, Inc.
ELTX · Pharmaceutical Preparations
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Ernexa Therapeutics Inc.
ERNAW · Pharmaceutical Preparations
ALX Oncology Holdings Inc
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Last updated: 24/09/2026